

Timothy S Pardee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2963133/publications.pdf>

Version: 2024-02-01

67
papers

3,051
citations

236612

25
h-index

161609

54
g-index

68
all docs

68
docs citations

68
times ranked

4597
citing authors

#	ARTICLE	IF	CITATIONS
1	Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	13.9	796
2	Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. <i>Blood</i> , 2013, 121, 4287-4294.	0.6	348
3	Mouse models of human AML accurately predict chemotherapy response. <i>Genes and Development</i> , 2009, 23, 877-889.	2.7	235
4	Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 770-778.	5.1	167
5	Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults. <i>Journal of Clinical Oncology</i> , 2014, 32, 2541-2552.	0.8	132
6	The Feasibility of Inpatient Geriatric Assessment for Older Adults Receiving Induction Chemotherapy for Acute Myelogenous Leukemia. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1837-1846.	1.3	117
7	The N-terminal Region of Yeast TFIIIB Contains Two Adjacent Functional Domains Involved in Stable RNA Polymerase II Binding and Transcription Start Site Selection. <i>Journal of Biological Chemistry</i> , 1998, 273, 17859-17864.	1.6	82
8	A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2014, 20, 5255-5264.	3.2	82
9	Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. <i>Cell Metabolism</i> , 2019, 29, 1217-1231.e7.	7.2	75
10	Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1988-1995.	1.3	72
11	A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 2060-2073.	3.2	72
12	The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). <i>Leukemia Research</i> , 2014, 38, 1184-1190.	0.4	68
13	A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas. <i>Future Oncology</i> , 2019, 15, 3189-3196.	1.1	64
14	Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). <i>Annals of Hematology</i> , 2014, 93, 47-55.	0.8	54
15	Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). <i>Journal of Geriatric Oncology</i> , 2016, 7, 24-31.	0.5	48
16	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020, 4, 696-705.	2.5	44
17	A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0164244.	1.1	43
18	Mitochondria in cancer metabolism, an organelle whose time has come?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 96-102.	3.3	42

#	ARTICLE	IF	CITATIONS
19	Animal models of leukemia: any closer to the real thing?. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 63-76.	2.7	40
20	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. <i>Leukemia</i> , 2020, 34, 2903-2913.	3.3	38
21	Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. <i>Blood</i> , 2012, 119, 3561-3570.	0.6	37
22	The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. <i>Future Oncology</i> , 2016, 12, 2009-2020.	1.1	33
23	Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance). <i>Blood</i> , 2014, 124, 8-8.	0.6	31
24	Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. <i>Blood</i> , 2020, 136, 2715-2719.	0.6	29
25	Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. <i>Experimental Hematology</i> , 2011, 39, 473-485.e4.	0.2	27
26	Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study. <i>Future Oncology</i> , 2019, 15, 3197-3208.	1.1	23
27	High dose cytarabine, mitoxantrone and L-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. <i>Leukemia Research</i> , 2015, 39, 945-949.	0.4	21
28	Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study. <i>Blood</i> , 2013, 122, 357-357.	0.6	20
29	The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. <i>Oncotarget</i> , 2014, 5, 4170-4179.	0.8	17
30	Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. <i>Leukemia Research</i> , 2015, 39, 229-235.	0.4	16
31	Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. <i>Journal of Geriatric Oncology</i> , 2020, 11, 410-416.	0.5	16
32	Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia. <i>Journal of Clinical Pathology</i> , 2015, 68, 236-240.	1.0	15
33	Overexpression of MN1 Confers Resistance to Chemotherapy, Accelerates Leukemia Onset, and Suppresses p53 and Bim Induction. <i>PLoS ONE</i> , 2012, 7, e43185.	1.1	13
34	Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. <i>Leukemia Research</i> , 2013, 37, 112-116.	0.4	13
35	Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. <i>Experimental Hematology</i> , 2013, 41, 180-188.e4.	0.2	13
36	Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. <i>Nature Communications</i> , 2022, 13, 1673.	5.8	13

#	ARTICLE	IF	CITATIONS
37	Improving nucleoside analogs via lipid conjugation: Is fatter any better?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 46-56.	2.0	12
38	The prognostic value of standardized phase angle in adults with acute leukemia: A prospective study. <i>Cancer Medicine</i> , 2020, 9, 2403-2413.	1.3	12
39	Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. <i>Leukemia Research</i> , 2017, 62, 51-55.	0.4	10
40	The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML. <i>PLoS ONE</i> , 2014, 9, e112619.	1.1	8
41	Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia. <i>Supportive Care in Cancer</i> , 2019, 27, 2877-2884.	1.0	7
42	Efficacy of 10-day decitabine in acute myeloid leukemia. <i>Leukemia Research</i> , 2021, 103, 106524.	0.4	7
43	Yeast and Human RNA Polymerase II Elongation Complexes: Evidence for Functional Differences and Postinitiation Recruitment of Factors. <i>Eukaryotic Cell</i> , 2003, 2, 318-327.	3.4	6
44	Subcutaneous panniculitis-like T cell lymphoma with mesenteric involvement. <i>Journal of Hematopathology</i> , 2013, 6, 155-159.	0.2	5
45	TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 4062-4062.	0.6	5
46	A single-arm, open-label, phase I study of CPI-613 (Devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4635-4635.	0.8	4
47	The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia. <i>PLoS ONE</i> , 2017, 12, e0179798.	1.1	3
48	Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML. <i>Blood</i> , 2018, 132, 1355-1355.	0.6	3
49	Altered Lipid and Mitochondrial Metabolism Are Viable Targets in Acute Leukemia,. <i>Blood</i> , 2011, 118, 3618-3618.	0.6	3
50	High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly. <i>Blood</i> , 2013, 122, 2700-2700.	0.6	2
51	Re-induction therapy in adult patients with acute myeloid leukemia with ≥20 % blasts: A retrospective cohort study. <i>Leukemia Research</i> , 2021, 111, 106731.	0.4	2
52	Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML). <i>Cancer Letters</i> , 2022, 535, 215659.	3.2	2
53	A symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) to maintain physical function.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12009-12009.	0.8	1
54	Acute Myeloid Leukemia in Older Adults. , 2020, , 501-520.		1

#	ARTICLE	IF	CITATIONS
55	Feasibility of a Symptom-Adapted Physical Activity Intervention during Induction Chemotherapy for Older Adults with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2102-2102.	0.6	1
56	Tailoring a physical activity intervention to older adults receiving intensive chemotherapy for acute myeloid leukemia (AML): One size does not fit all. <i>Journal of Geriatric Oncology</i> , 2022, 13, 511-515.	0.5	1
57	The Novel Phospholipid Mimetic KPC34 Is Highly Active Against Acute Myeloid Leukemia with Activated Protein Kinase C. <i>Translational Oncology</i> , 2020, 13, 100780.	1.7	0
58	A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BILT-04).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4158-TPS4158.	0.8	0
59	The Flt3 ITD Accelerates An Already Established Myeloid Leukemia and Alters Chemotherapy Response In Vitro and In Vivo in a p53 Dependent Manner.. <i>Blood</i> , 2009, 114, 1719-1719.	0.6	0
60	Over Expression of MN1 Accelerates Leukemia Onset and Confers Resistance to Chemotherapy by Suppression of p53 and Bim. <i>Blood</i> , 2011, 118, 2501-2501.	0.6	0
61	Unique Dual Targeting of Thymidylate Synthase and Topoisomerase1 by FdUMP[10] Results in High Efficacy Against AML and Low Toxicity. <i>Blood</i> , 2011, 118, 2584-2584.	0.6	0
62	Thymidylate Synthase Inhibition with the Novel Fluoropyrimidine FdUMP[10] Is Highly Effective Against Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1505-1505.	0.6	0
63	The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2556-2556.	0.6	0
64	Pilot study of first-in-class antimitochondrial metabolism agent, CPI-613, as salvage monotherapy for small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20100-e20100.	0.8	0
65	Retrospective analysis of nadir bone marrow biopsies in predicting need for re-induction therapy in adult acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18509-e18509.	0.8	0
66	Association between glycemic control, age, and outcomes among intensively treated patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10043-10043.	0.8	0
67	Acute Myeloid Leukemia in Older Adults. , 2019, , 1-20.		0